Archive · 7 Nov 2025
New Obesity Drugs Show Promise but Aren't a 'Miracle Cure'
Imagine your body needs the right amount of energy, like a car needs the right amount of fuel.
Sometimes, people's bodies store too much energy as fat, which is called obesity.
This can make them sick.
Doctors have found new medicines that can help people lose weight by making them feel fuller and helping their bodies manage sugar better.
These medicines have shown good results, helping people lose a noticeable amount of weight.
However, doctors say these pills aren't magic and can't completely cure obesity on their own.
This is because obesity has many causes, like what we eat, our environment, our genes, and even our feelings.
The new medicines help, but people still need to eat healthy foods and exercise.
It's also important to help everyone have a healthy environment and good access to healthy food, not just rely on medicine.
We need to look at all the reasons why people become obese to truly help them.
Obesity affects over 1 billion people globally, with France seeing a rise to 17% prevalence in 2020.
New GLP-1 analog medications show effectiveness in weight loss and improving metabolic health when combined with lifestyle changes.
Despite their efficacy, these drugs are not considered a cure for obesity due to its complex, multifactorial causes.
Factors contributing to obesity include genetics, environment, endocrine disruptors, psychological, and sociological influences.
Experts emphasize that a comprehensive, multidisciplinary approach focusing on prevention and addressing all underlying causes is crucial for sustainable obesity management.
- Who
- World Health Organisation, researchers, healthcare providers, patients, and pharmaceutical companies.
- What
- The increasing prevalence of obesity globally and in France, the advent of new GLP-1 analog medications, and the limitations of these drugs as a sole solution.
- When
- Obesity prevalence has doubled between 1990 and 2022; recent data from 2020 shows 17% prevalence in France; new GLP-1 medications are a recent addition to therapeutic options.
- Where
- Globally, with specific mention of France.
- Why
- Obesity is a complex, multifactorial disease influenced by genetics, hormones, environment, psychological, and sociological factors, meaning new drugs alone cannot address all underlying causes.
Curative Approach
Preventive Approach
Focus of Current Treatments
Curative Approach
GLP-1 analogs are seen as a treatment for developed obesity, representing a curative strategy.
Preventive Approach
Preventive measures, like lifestyle and dietary changes, are often considered insufficient, but the methods for developing these measures and factors hindering their implementation are rarely questioned.
Factors Addressed
Curative Approach
GLP-1 analogs target specific biological mechanisms like insulin production and satiety.
Preventive Approach
Prevention needs to address a wide range of factors including access to unhealthy foods, economic interests over health, environmental pollutants, land-use planning for active mobility, and socio-economic/psychological impacts.
Responsibility and Guilt
Curative Approach
Medication offers a more direct intervention for an existing condition.
Preventive Approach
Public health messages often place responsibility on individuals, which can be guilt-inducing, and overlook broader causal factors.
- Global Obesity Prevalence
- More than 1 billion people affected in 2022 (880 million adults, 160 million children).
- Obesity Definition
- Abnormal or excessive fat accumulation posing a health risk (BMI > 30 kg/m²).
- New Obesity Medications
- GLP-1 analogs like liraglutide, semaglutide, and tirzepatide.
- Mechanism of GLP-1 Analogs
- Increase insulin production, improve glucose absorption, affect satiety, and delay gastric emptying.
- Effectiveness of GLP-1 Analogs
- Demonstrated effectiveness in clinical trials for weight loss (e.g., 15% with semaglutide over 68 weeks) and improvements in cardiovascular/metabolic parameters when combined with diet and exercise.
- Cost of GLP-1 Analogs
- Estimated at around 300 euros per month per patient, not currently reimbursed by French national health insurance.
- Prevalence in France
- 17% in 2020, up from 8.5% in 1997.